Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (55)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Grdina, D. J.
Right arrow Articles by Perrin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grdina, D. J.
Right arrow Articles by Perrin, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 Oxford University Press

research-article

The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation

David J. Grdina 1 2, Yasushi Kataoka 1, Ivan Basic 3 and Jane Perrin 1

1Biological and Medical Research Division, Argonne National Laboratory Argonne, IL 60439
2Department of Radiation and Cellular Oncology. University of Chicago Chicago, IL 60637, USA
3Visiting Scientist, University of Zagreb Zagreb, Croatia

An in vitro T-lymphocyte cloning technique has been applied to study the effects of JANUS fission-spectrum neutron irradiation and the radioprotector S-2-(3-aminopropylamino) ethylphosphorothioic acid (WR-2721) on the subsequent development of somatic mutations at the hypoxanthine-guanine phosphoribosyl transferase (hprt) locus in hybrid B6CF1 male mice. In control studies performed to establish an in vitro cloning technique, the mutant frequencies of splenic T-lymphocvtes, as a result of exposure to a 100 cGy dose of neutrons, increased with time from a control level of 9 × 10–7 to a maximum value of 1.7 × 10–5 at 56 days following irradiation. Between 56 and 150 days after irradiation, mutant frequencies were observed to plateau and remain stable. All subsequent determinations were performed at 56 days following the experimental treatment ofanimals. WR-2721 at a dose of 400 mg/kg was effective in protecting against the induction of hprt mutants (i.e. a mutant frequency reduction factor, MFRF) following the largest dose of neutrons used (i.e. 150 cGy), whether it was administered i.p. 30 min before, 5 min after, 3 h after, or three times at 3, 24, and 48 h after, as evidenced by MFRFs of 6.0, 6.6, 4.8 and 5.8 respectively. The antimutagenic effectiveness of WR-2721 administered 30 min prior to irradiation was unaffected, even when the dose was reduced to 200 mg/kg, MFRF = 7.0; 100 mg/kg, MFRF = 3.8; and 50 mg/kg, MFRF = 8.9. These findings confirm our earlier report using the radioprotector N-(2-mercaptoethyl)-1,3-diaminopropane (WR-1065) under in vitro conditions, and demonstrate that these agents can be used as effective antimutagens even when they are administered up to 3 h following radiation exposure.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
L. Liang, M. S. Mendonca, L. Deng, S. C. Nguyen, C. Shao, and J. A. Tischfield
Reduced Apoptosis and Increased Deletion Mutations at Aprt Locus In vivo in Mice Exposed to Repeated Ionizing Radiation
Cancer Res., March 1, 2007; 67(5): 1910 - 1917.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Dai, A. M. Holmes, T. Nguyen, S. Davies, D. P. Theele, C. Verschraegen, and K. K. Leslie
A Potential Synergistic Anticancer Effect of Paclitaxel and Amifostine on Endometrial Cancer
Cancer Res., October 15, 2005; 65(20): 9517 - 9524.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. C. Acosta, C. Richard, M. D. Delgado, M. Horita, M. G. Rizzo, J. L. Fernandez-Luna, and J. Leon
Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells
Mol. Cancer Ther., September 1, 2003; 2(9): 893 - 900.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.